This page is updated frequently with new Peritoneal-related patent applications. Subscribe to the Peritoneal RSS feed to automatically get the update: related Peritoneal RSS feeds. RSS updates for this page: Peritoneal RSS
Peritoneal dialysis fluid
Deka Products Limited Partnership
Fluid line autoconnect apparatus and methods for medical treatment system
Baxter Healthcare S.a.
Optimizing peritoneal dialysis using a patient hand-held scanning device
|| List of recent Peritoneal-related patents
| Partially absorbable fiber-reinforced composites for controlled drug delivery|
This invention describes a partially absorbable, fiber-reinforced composite in the form of a ring, or a suture-like thread, with modified terminals for use as a controlled delivery system of at least one bioactive agent, wherein said composite comprising an absorbable fiber construct capable of providing time-dependent mechanical properties of a biostable elastomeric matrix containing an absorbable microparticulate ion-exchanger to modulate the release of the bioactive agent(s) for a desired period(s) of time at a specific biological site; this can be a vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop or subcutaneous tissue. Such drug delivery systems can be used for the local administration of at least one bioactive agent, including those used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral agents as well as for cancer treatment..
|Peritoneal dialysis fluid|
The present invention is a sterile peritoneal dialysis fluid, including an acidic first liquid containing only icodextrin and 0 to 2.34 g/l of sodium chloride, and an alkaline second liquid containing an alkaline ph regulator, in which the first liquid after sterilization has a ph of 5.0 to 5.5, the second liquid after sterilization has a ph of 6.5 to 7.5, and a mixture of the first liquid and the second liquid after sterilization has a ph of 6.0 to 7.5. The present invention can provide a peritoneal dialysis fluid containing icodextrin, in which the stability of icodextrin during the heat sterilization and the subsequent storage can be improved to the maximum, and the ph of the peritoneal dialysis fluid is close to the physiological range..
Terumo Kabushiki Kaisha
|Fluid line autoconnect medical treatment system|
A medical infusion fluid handling system, such as an automated peritoneal dialysis system, may be arranged to de-cap and connect one or more lines (such as solution lines) with one or more spikes or other connection ports on a fluid handling cassette. This feature may reduce a likelihood of contamination since no human interaction is required to de-cap and connect the one or more lines and the one or more spikes.
Deka Products Limited Partnership
|Optimizing peritoneal dialysis using a patient hand-held scanning device|
A handheld personal communication apparatus for dialysis includes: a reader to (i) read a marking displayed on a dialysis fluid container to acquire data concerning at least one of a dialysis fluid type or a dialysis fluid volume from the marking, and/or (ii) receive a patient weight signal from a weight scale; a processor using at least one of the dialysis fluid type, dialysis fluid volume, or patient weight to determine a dialysis dwell time for at least one cycle of a dialysis therapy, the dialysis dwell time being a time to achieve, over the at least one cycle, at least one of (a) a specified ultrafiltrate level, (b) a urea removal level, or (c) a creatinine removal level; and an output interface providing an indication to the patient of a completion of the dialysis dwell time.. .
Baxter Healthcare S.a.
|Portal and management of dialysis therapy|
System and method for point-of-care monitoring of neutrophils in a peritoneal dialysis sample with the use of a microfluidic system. The immunoassay based chip is configured to bound neutrophils to a microfluidic channel surface while leaving auxiliary cells and particles unattached and suspended in the sample and flushable with a wash buffer.
|Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer|
The invention discloses high levels of receptors for clostridium perfringens enterotoxin (cpe) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of cpe is disclosed.
|Viral fusion protein treatment for ccr8 mediated diseases|
Compositions, methods, and kits are provided for treating ccr8 mediated diseases with applicability to atopic dermatitis and potential applicability to asthma, prurigo nodularis, nummular dermatitis, neurodeimatitis, and lichen simplex chronicus and some lymphomas, multiple sclerosis, acquired immunodeficiency disease, peritoneal adhesions, kaposi's sarcoma and atherogenesis—the expression of all of which, at least in part, is mediated by cells expressing the chemokine receptor ccr8. The compositions include proteins and fusion proteins from molluscum contagiosum virus (mcv) or variants, analogs and derivatives thereof which exhibit inhibitory activity.
|Liposome composition for use in peritoneal dialysis|
The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the ph within the liposomes differs from the ph in the intraperitoneal cavity and wherein the ph within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes.
|Hemodialysis and peritoneal dialysis systems having electrodialysis and electrodeionization capabilities|
Systems and methods for hemodialysis or peritoneal dialysis having integrated electrodialysis and electrodeionization capabilities are provided. In an embodiment, the dialysis system includes a carbon source, a urease source, an ed/edi unit.
Baxter Healthcare S.a.
|Systems and methods for performing peritoneal dialysis|
Systems and methods for providing multiple pass continuous flow dialysis are provided. In an embodiment, a system for providing peritoneal dialysis includes a catheter in communication with a peritoneal cavity, a fluid loop in fluid communication with the catheter and capable of circulating a therapy fluid into, through and out of the patient's peritoneal cavity, a multi-line fluid circuit, the multi-line fluid circuit in fluid communication with the fluid loop and including a bypass line coupled to a discharge fluid line, and a cycler including a plurality of valves, the cycler programmed to operate the plurality of valves to selectively (i) discharge therapy fluid from the multi-line fluid circuit via the discharge fluid line or (ii) bypass the discharge fluid line via the bypass line and circulate the therapy fluid a plurality of times through the fluid loop prior to exiting the multi-line fluid circuit via the discharge fluid line..
Baxter Healthcare S.a.
Composite absorbable/biodegradable rings for controlled drug delivery
A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer..
Method of inexpensive transepithelial dialysis with hot water bath and sorbents
Current technologies to treat end stage renal disease (esrd) include peritoneal dialysis, hemodialysis and transplantation all of which are expensive. This invention is an inexpensive method to decrease body toxins that requires immersion of a body in a hot water bath with sorbents.
Method of mending a groin defect
A method of mending a groin defect such as an indirect inguinal hernia, a direct inguinal hernia, and/or a femoral hernia. A space between the external oblique aponeurosis and the internal oblique aponeurosis is dissected superiorly and laterally to create a site for receiving a lateral portion of a prosthetic repair patch.
Bard Shannon Limited
Device having electrodes for bio-impedance measurement for dialysis
Electrodes for a bio-impedance measuring device or a body composition monitor, the electrodes being integral with or being attached to a surface of at least one device belonging to a group of electronic and/or non-electronic devices used in the preparation of a dialysis treatment or during dialysis, in particular during peritoneal dialysis, the group preferably consisting of organizers of a continuous ambulatory peritoneal dialysis system (capd), automated peritoneal dialysis devices, automated peritoneal dialysis-cyclers (apd-cycler), bioelectrical impedance analyzers (bia), body composition monitors (bcm), hand-held electrodes holders for the electrodes, and dialysis apparatuses. Devices and methods used during dialysis are also described..
Fresenius Medical Care Deutschland Gmbh
A connection device, to connect two ends of respective ducts to another flexible duct in the field of the peritoneal dialysis including a closed container containing two nozzle-like terminal ends of a y-shaped branch of a flexible duct; a removable connection member configured to be engaged/disengaged on the closed container, containing the ending portions of the respective ducts shaped to couple/uncouple with the nozzle-like terminal ends, a distal end of the container and the connecting member are shaped to couple according to a guiding scheme with prismatic joint; a closure with mobile walls on the closed container is actuated in opening and closing by the contact of a projecting septum of the connection member upon the connection/disconnection between the closed container and the connection member; and a closure with removable tear film arranged at the ending portions of the ducts to close the respective sections opened inside the connection member.. .
Glomeria Therapeutics S.r.l.
Solution for peritoneal dialysis
The present invention further relates to a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.. .
Devices, systems, and methods for diagnosing and delivering therapeutic interventions in the peritoneal cavity
A device and system are described that are capable of isolating at least one targeted tissue and forming an anastomosis between two internal body structures though a completely endoscopic procedure. Further, the device and system described generally comprise two tubular members that are capable of moving in a telescopic fashion relative to one another.
Peritoneal dialysis connection using ultraviolet light emitting diodes
peritoneal dialysis systems and methods are provided by the present disclosure. In a general embodiment, a peritoneal dialysis system includes a peritoneal dialysis fluid supply, a supply line in fluid communication with the peritoneal dialysis fluid supply, the supply line terminating at a supply connector, a patient connector in fluid communication with a patient's indwelling catheter, and a device configured to be placed around at least one of the supply connector and the patient connector during a connection of the supply connector and the patient connector, the device including an ultraviolet (“uv”) transmissive material to allow uv energy to be directed inwardly through the device towards a mating surface of the at least one of the supply connector and the patient connector during the connection of the supply connector and the patient connector..
Baxter Healthcare S.a.
Method of placing a drainage catheter system
The present disclosure describes a single incision method of placing a drainage catheter in the peritoneal cavity.. .
Therapeutic methods for peritoneal carcinomatosis
Described herein are methods and medicaments useful for treating peritoneal carcinomatosis by administering anti-ctgf agents, particularly anti-ctgf antibodies. Methods for prognosing individuals with perinoteal carcinomatosis are also provided.
Body fluid expanders comprising n-substituted aminosulfonic acid buffers
A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein..
System and monitoring and control of ultrafiltration volume during peritoneal dialysis using segmental bioimpedance
A peritoneal dialysis (pd) system for infusing a volume of pd solution into a patient's peritoneal cavity in order to perform peritoneal dialysis on the patient includes a peritoneal cavity monitor (pcm) that measures this volume of fluid in the patient's peritoneal cavity by segmental bioimpedance spectroscopy (sbis), to thereby determine an ultrafiltration volume of fluid in the patient's peritoneal cavity, and a switch, controlled by the pcm, for filling the patient's peritoneal cavity and draining the patient's peritoneal cavity when the ultrafiltration volume is unchanged over time, significantly decreased, or decreasing at a significant rate.. .
Methods and devices for diagnostic and therapeutic interventions in the peritoneal cavity
A novel approach to diagnostic and therapeutic interventions in the peritoneal cavity is described. More specifically, a technique for accessing the peritoneal cavity via the wall of the digestive tract is provided so that examination of and/or a surgical procedure in the peritoneal cavity can be conducted via the wall of the digestive tract with the use of a flexible endoscope.
Apollo Endosurgery, Inc.
Exterior cap of transfer set for peritoneal dialysis
An exterior cap of transfer set for peritoneal dialysis, including: a cylindrical cap unit to which the end connector of the peritoneal transfer set is coupled; a guide unit that is coupled to the cap unit, extends to the peritoneal transfer set to provide an expanding internal space, and guides the end connector of the peritoneal transfer set into the cap unit; and a coupling-separating unit that combines the cap unit and the guide unit with each other and separates the cap unit and the guide unit in accordance with selection of a user.. .
Research Cooperation Foundation Of Yeungnam University
Dipeptide mimetics of ngf and bdnf neurotrophins
The invention relates to compounds having either agonist or antagonist activities for the neurotrophins ngf and bdnf and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure.
Uchrezhdenie Rossiiskoi Akademii Meditsynskikh Nauk Nauchno-issledovatelsky Institut Farmakologii
User wearable device for carrying peritoneal dialysis catheter
Improvements in an easily wearable catheter. A housing secures the components of the catheter, i.e.
Line leaf inula flower lactone a and methods for preparing and using the same for treating myocarditis
The compound shows positive therapeutic activity against coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone a prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d.
Compounds as rearranged during transfection (ret) inhibitors
This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. .
Glaxosmithkline Intellectual Property Development Limited
Method and performing retro peritoneal dissection
Cmos or ccd camera device. According to one embodiment, fiber optics run semi-circumferentially or along walls of the cannula/dilator and terminate at about a centimeter from the distal end of the cannula/dilator, thereby preventing illumination from “bottoming out” at the floor of the incision.
Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy
Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 μm and about 400 μm.
Baxter International Inc.
Automated peritoneal dialysis system using stepper motor
An embodiment of a peritoneal dialysis system includes an enclosure, a door hingedly attached to the enclosure, a stepper motor housed by the enclosure, a solid pump piston in operable communication with the stepper motor and including a solid pump shaft attached to or integrally formed with a solid pump head, and a disposable unit contacting the enclosure and the door. The disposable unit includes a moveable membrane operable with the solid pump head.
Baxter Healthcare S.a.
Systems with disposable pumping unit
An embodiment of a peritoneal dialysis system includes a peritoneal dialysis hardware unit having a housing with a first opening, a door coupled to the housing and having a second opening, and a solid pump piston having a solid piston shaft attached to or integrally formed with a solid piston head. The system also includes a stepper motor operable to cause the solid pump piston to translate; a disposable pumping unit having a first and a second opposing surface, and a fluid pump receptacle extending from the first and second surface to fit within the second opening.
Baxter Healthcare S.a.
Nitrogenous heterocyclic derivatives and their application in drugs
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis..
Sunshine Lake Pharma Co., Ltd.
Dye conjugated peptides for fluorescent imaging
The present application discloses compositions and methods of use of peptide targetable constructs for detection, diagnosis and/or imaging of cancer. In preferred embodiments, the targetable construct comprises at least one hapten, at least one fluorescent probe, a chelating moiety and a group iiia metal-18f complex attached to the chelating moiety.
Peritoneal dialysis machine
A method for operating a dialysis cassette including a flexible membrane that covers a pump chamber includes allowing a source of fluid to fluidly communicate with the pump chamber of the dialysis cassette, filling the pump chamber with the fluid from the source, mechanically extending the flexible membrane into the pump chamber with a piston head to expel the fluid from the pump chamber through a flow path, and directly sensing a pressure of the fluid flowing through the flow path at a location of the dialysis cassette adjacent to the pump chamber and using the sensed pressure to perform a test prior to delivering fluid to a patient.. .
Baxter Healthcare S.a.
Medicament, method, and drug delivery device for treatment of ovarian cancer
Drug delivery devices, medicaments, and methods are provided for the intraperitoneal treatment of ovarian cancer. An implantable device for drug delivery includes an elongated, flexible device having a housing defining a reservoir that contains a drug in solid or semi-solid form, and configured to be wholly deployed within the peritoneal cavity of a patient and continuously release a therapeutically effective amount of the drug over a period of at least 24 hours.
The General Hospital Corporation
Methods and compositions for treating recurrent cancer
The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as nab-paclitaxel or abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.. .
Abraxis Bioscience, Llc
Compositions for improved tissue oxygenation by peritoneal ventilation
Compositions and methods for improving transperitoneal oxygen uptake during peritoneal ventilation for extrapulmonary oxygenation of an organism or individual organs in preferably life-threatening case of need, such as pulmonary failure or circulatory shock, are disclosed. Such deficiencies can be addressed by transperitoneal administration of oxygen via a gas introduced into the abdominal cavity.
Sangui Biotech International, Inc.
System and administering peritoneal dialysis
Systems and methods are provided for improved techniques associated with administering peritoneal dialysis. Embodiments of the invention relate to the continuous introduction and circulation of dialysate fluid in and through the peritoneal cavity.
Apparatus and ovarian cancer screening
An apparatus and method are provided for sampling the distal tube, fimbria and/or ovary, includes advancing a device into the peritoneal cavity and sampling material on or adjacent to the distal tube, fimbria or ovary.. .
Mkt Enterprises, Llc
Drug elution for in vivo protection of bio-sensing analytes
A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more therapeutic agents.
Fluid pumping systems, devices and methods
Embodiments of the present invention relate generally to certain types of reciprocating positive-displacement pumps (which may be referred to hereinafter as “pods,” “pump pods,” or “pod pumps”) used to pump fluids, such as a biological fluid (e.g., blood or peritoneal fluid), a therapeutic fluid (e.g., a medication solution), or a surfactant fluid. The pumps may be configured specifically to impart low shear forces and low turbulence on the fluid as the fluid is pumped from an inlet to an outlet.
Deka Products Limited Partnership
Self-warming peritoneal dialysis solution bag
A self-warming peritoneal dialysis solution bag is provided that contains a peritoneal dialysis solution. The solution bag can have an outer surface and a non-electric, warming patch adhered or affixed to the outer surface.
Fresenius Medical Care Holdings, Inc.
Molluscum contagiosum viral fusion protein treatment for atopic dermatitis diseases
Compositions, methods, and kits are provided for treating ccr8 mediated diseases with applicability to atopic dermatitis and potential applicability to asthma, prurigo nodularis, nummular dermatitis, neurodermatitis, and lichen simplex chronicus and some lymphomas, multiple sclerosis, acquired immunodeficiency disease, peritoneal adhesions, kaposi's sarcoma and atherogenesis—the expression of all of which, at least in part, is mediated by cells expressing the chemokine receptor ccr8. The compositions include proteins and fusion proteins from molluscum contagiosum virus (mcv) or variants, analogs and derivatives thereof which exhibit inhibitory activity.
Method of mending a groin defect
A method of mending a groinal defect such as an indirect inguinal hernia, a direct inguinal hernia, and/or a femoral hernia. A space between the external oblique aponeurosis and the internal oblique aponeurosis is dissected superiorly and laterally to create a site for receiving a lateral portion of a prosthetic repair patch.
Bard Shannon Limited
Transperitoneal prolapse repair system and method
A prolapse repair system and procedure are provided. The system can include one or more anchor devices and one or more extending members, such as a suture.
Hemodialysis and peritoneal dialysis systems having electrodeionization capabilities
Systems and methods for hemodialysis or peritoneal dialysis having integrated electrodeionization capabilities are provided. In an embodiment, the dialysis system includes a carbon source, a urease source and an electrodeionization unit.
Emd Millipore Corporation
Popular terms: [SEARCH]
Peritoneal topics: Peritoneal, Peritoneal Dialysis, Peritoneal Cavity, Dialysis System, Intraperitoneal, Abdominal Cavity, Hemodialysis, Anastomosis, Wireless Communication Device, Colorectal, Hydrogen Sulfide, Sulfonamide, Ultraviolet, Ultraviolet Light, Subcutaneous
Follow us on Twitter
This listing is a sample listing of patent applications related to Peritoneal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Peritoneal with additional patents listed. Browse our RSS directory or Search for other possible listings.